Exelixis, Inc.
1851 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 650-837-7000
Website: http://www.exelixis.com/
828 articles about Exelixis, Inc.
-
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
9/12/2023
Exelixis, Inc. and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September 2023
8/31/2023
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September.
-
Following a late-stage victory on Monday, Exelixis on Thursday reported another Phase III win for its tyrosine kinase inhibitor Cabometyx—this time in advanced neuroendocrine tumors.
-
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
8/24/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was observed at an interim analysis.
-
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
8/23/2023
Exelixis, Inc. announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.
-
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
8/21/2023
Exelixis, Inc. and Ipsen announced that the global phase 3 CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically significant improvement in progression-free survival at the primary analysis.
-
After sustaining two Phase III fails, Roche and Exelixis finally reported a late-stage win for their combination regimen of Tecentriq and Cabometyx in metastatic castration-resistant prostate cancer.
-
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
7/18/2023
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close.
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June 2023
5/30/2023
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June.
-
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
-
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
5/7/2023
Exelixis, Inc. announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately.
-
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
5/4/2023
Adagene Inc. announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.
-
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
5/3/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m. ET / 10:40 a.m. PT.
-
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
4/25/2023
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close.
-
Exelixis Advances Board Refreshment Plan
4/13/2023
Exelixis, Inc. announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders.
-
Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.
-
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
4/5/2023
Funds managed by Farallon Capital Management L.L.C. own approximately 7.2% of the outstanding shares of Exelixis, Inc., making it the Company’s largest active shareholder.
-
Exelixis Announces $550 Million Share Repurchase Program
3/20/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023.
-
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
3/13/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. PT.
-
Phase III data showed the combination of Roche’s Tecentriq and Exelixis’ Cabometyx fell short of its primary endpoint in renal cell carcinoma.